Certolizumab pegol in active rheumatoid arthritis

被引：0

作者：

Aarat M. Patel

Larry W. Moreland

机构：

[1] University of Pittsburgh,Division of Rheumatology and Clinical Immunology, Division of Pediatric Rheumatology

[2] Children’s Hospital,Division of Rheumatology and Clinical Immunology

[3] University of Pittsburgh,undefined

来源：

关键词：

Adalimumab; Active Rheumatoid Arthritis; Certolizumab Pegol; ACR20 Response Rate; Total Sharp Score;

D O I：

10.1007/s11926-009-0056-7

中图分类号：

学科分类号：

摘要：

引用

页码：311 / 312

页数：1

共 15 条

[1] Maini R.(1999)Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932-1939
[2] St Clair E.W.(2004)Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 1400-1411
[3] Breedveld F.(2007)Maintenance therapy with certolizumab pegol for Crohn’s disease N Engl J Med 357 239-250
[4] Keystone E.C.(2009)Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Ann Rheum Dis 68 797-804
[5] Kavanaugh A.F.(2009)Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study Ann Rheum Dis 68 805-811
[6] Sharp J.T.(undefined)undefined undefined undefined undefined-undefined
[7] Schreiber S.(undefined)undefined undefined undefined undefined-undefined
[8] Khaliq-Kareemi M.(undefined)undefined undefined undefined undefined-undefined
[9] Lawrance I.C.(undefined)undefined undefined undefined undefined-undefined
[10] Smolen J.(undefined)undefined undefined undefined undefined-undefined